Medicare has begun its long-awaited negotiations with drugmakers, an effort aimed at getting them to reduce the costs of the first 10 Part D drugs selected under the Medicare Drug Price Negotiation Program.
Negotiations are slated to end August 1.The new negotiated prices for the drugs are expected to be announced by September 1, with an effective date of January 2026.
Medicare — the country’s largest prescription drug buyer — intends to choose up to 60 more drugs for the program during the next four years and up to 20 additional drugs per year after that.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Drugmakers participating in the talks are: AstraZeneca AB; Boehringer Ingelheim; Bristol Myers Squibb; Immunex; Janssen Biotech; Janssen Pharmaceuticals; Merck & Co.; Novartis Pharmaceuticals; Novo Nordisk; and Pharmacyclics.
Medicare selected the first 10 drugs for the program last year. The drugs, covered under Part D, are: Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara and Fiasp/NovoLog.
In 2022, about 9 million Medicare beneficiaries were prescribed the drugs selected for this first round of the program. Some of these seniors were paying nearly $6,500 in out-of -pocket costs for just one of the drugs, President Joe Biden said in a February 1 announcement about the progress of negotiations.
Last month, drugmakers raised prices on six of the 10 the drugs even after all 10 were priced 3- to 8-times higher in the U.S, than in other countries, the administration said in a separate statement.
Under the program, which is authorized under the Inflation Reduction Act, Medicare has the authority for the first time to directly negotiate prices for certain high-cost, single-source drugs that do not have generic or biosimilar competition.
“This is the first time ever that Medicare is not accepting the drug prices the pharmaceutical companies set,” the administration said.
By contrast, it added, Medicaid, the Department of Defense and the Veterans Health Administration already had the authority to negotiate drug prices and they pay less than Medicare, on average, for top-selling, brand-name drugs.
$79,000 vs. $16,000 for Stelara
Drugmakers, which have filed a total of nine lawsuits attempting to block the Medicare Drug Price Negotiation Program, remain under fire on and off Capitol Hill for charging exorbitantly higher prices in the U.S. than in other countries.
That situation was the focus of a Senate committee hearing earlier this week when executives from Johnson & Johnson, Merck and Bristol Myers Squibb were grilled.
In the U.S., Johnson & Johnson charges $79,000 for arthritis medicine Stelara, while that same product can be purchased for $16,000 in the U.K., Sen. Bernie Sanders (I-VT) said during the hearing.
Bristol Myers Squibb charges U.S. patients $7,100 for blood thinner Eliquis, but sells the same product for $900 in Canada and just $650 in France, he said. Merck charges U.S. diabetes patients $6,900 for Januvia when that same product is only $900 in Canada and $200 in France, he added.
Sanders said that, despite discussions about how divided the nation is over many issues, one matter that people agree on is “the need to substantially lower the outrageously high price of prescription drugs in our country.” He cited an unspecified recent poll showing that 82% of Americans said the cost of prescription drugs is too high, with 73% saying the government is not doing enough to regulate drug prices.
Sanders charged that drugmakers are spending billions of dollars on executive compensation, stock buybacks as well as mergers and acquisitions, and passing the costs onto patients.
"Americans are forced to pay higher and higher prices for the drugs they need to survive," Sanders said. "And let's be clear, the overwhelming beneficiary of these high drug prices is the pharmaceutical industry."
Pricey insulin costs
In a separate announcement on February 1, the Health and Human Services’ (HHS) Office of the Assistant Secretary for Planning and Evaluation (ASPE) issued several reports with cost comparisons of prescription drugs in the U.S. versus those in other Organisation for Economic Co-operation and Development (OECD) countries.
Among ASPE's findings was the fact that U.S. prices for all branded and generic drugs in 2022 were nearly 3 times as high as those in 33 of the OECD countries.
“For every dollar paid in other countries for drugs, consumers in the United States pay $2.78,” according to the report. “The gap is widening over time as U.S. drug prices grow faster than drug prices in other countries and the mix of drugs changes.”
The U.S. gross prices for insulin — which was developed about 100 years ago and costs drugmakers about $10 a vial to produce — were on average nearly 10 times the price in the U.S. than they were in 33 OECD countries as well, said the Biden administration citing the report.
New website for beneficiaries
HHS has launched LowerDrugCosts.gov, a new website for Medicare beneficiaries with information related to the drug pricing provisions of the Inflation Reduction Act as well as resources for Medicare enrollees and other interested parties.
Related Content
-
Nine of the Biggest Regrets I See as a Financial PlannerCheck out this list of common regrets among older people and see if there’s something you can address in your own life while there’s still time.
-
Three Habits of My Most Successful Wealth Management Clients
Clients are more likely to meet their financial objectives if they’re totally honest, take action in a timely manner and are actively engaged.
-
How to Write a Check for a Wedding Gift
There are some guidelines to writing a check for a wedding gift for newlyweds.
-
What To Know About Chrysler's Jeep Grand Cherokee Recall
The Jeep Grand Cherokee recall concerns an issue that could cause a loss of vehicle control, NHTSA says.
-
Verizon's Latest Bundle Offers Netflix and AMC Plus for $25.99
The new bundle will save you around $6 a month but you need to act fast, Verizon says.
-
Healthcare Costs Top Concerns For Many Voters This Election Year, Study Shows
The top financial worries for most Americans are unexpected medical expenses and healthcare costs, according to a new KFF study.
-
What to Know About Toyota’s Recall of 381,000 Tacoma Trucks
Toyota issues recall, its fourth in a week, due to concerns with the rear axle assembly on certain trucks.
-
Delta Adds Second Solar Eclipse Flight On April 8
Delta follows Southwest with special flights that offer the chance to view the eclipse as the path of totality runs across 13 U.S. states.
-
What Checked Bag Fees Cost at Major Airlines After Recent Hikes
There's a growing list of airlines that have hiked baggage fees this year. Here's the latest on what you'll pay to check bags when you fly.
-
Healthcare System Still Reeling From UnitedHealth Cyberattack, AHA Says
The American Hospital Association says UnitedHealth's breach prevents many members from processing claims and checking patient eligibility for insurance coverage.
